A study that has included 103 patients with breast cancer who had developed metastasis, has proven that the administration of a biological therapy (trastuzumab) delayed the progression of the pathology between four and five years on average.
After using standard chemotherapy, this type of cancer usually recurs in less than two years. However, with this drug, which was administered to patients who had previously received chemotherapy, it was possible to prolong survival, reaching more than 60 months in cases in which tumor had disappeared.
This medication could be used for years without danger, while the use of chemotherapy should be limited because its toxic effects are greater than the benefits it brings.
Another positive data extracted from the research, in which 42 Spanish hospitals participated, was that the patients did not suffer an increase in side effects with this medication, for which the experts point out that it could be used for years without danger, unlike what happens with chemotherapy, whose use should be limited because its toxic effects are greater than the benefits it brings.
The new treatment is part of what specialists call directed therapy, and has significantly improved the prognosis of patients with Breast cancer HER-2 positive in advanced stage, by facilitating better control of the disease, which allows to prolong the time during which the tumor does not progress.